| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0597f9c318d2aeca86db94711c516383 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-193 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-19 |
| filingDate |
2019-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4326f710cf3f65dd4b4ddc480d69dd50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd319b9b3a20c5f4a8a9c4ea10c398a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1a931b719bf5117052355b75e969a9d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b9426f82fec1b742d295ad22dc01829
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31a29823526938efe20995591b018cb3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6df73fa3c86630ef6b6673d1ca5072d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16a05a749a81052f1974336f8e9eca68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a3408ed314d9f2c7f202a276c12de7d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a270716d93ffefc54bf3fd9efd623dc |
| publicationDate |
2020-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2019231317-A1 |
| titleOfInvention |
Methods of treatment with pegfilgrastim and romiplostim |
| abstract |
The present invention concerns methods comprising co-administration of pegfilgrastim and romiplostim for treatment of diseases and conditions characterized by low neutrophil levels (neutropenia) and/or low platelet levels (thrombocytopenia). The present invention concerns an enhanced effect on neutrophil levels and on platelet levels resulting from co-administration of pegfilgrastim and romiplostim. The present invention further concerns a method of treating a patient who has been exposed to radiation, which comprises administering romiplostim at a dose of about 1 to about 10 g/kg. The invention further concerns such methods wherein a single dose of romiplostim is administered to the patient and wherein romiplostim is administered about 24 hours or less after the radiation exposure. The invention further concerns treatment with romiplostim and pegfilgrastim for radiation exposure. Such methods relate to treatment of acute radiation syndrome and treatment to counteract the effects of radiation therapy and other sources of radiation exposure. |
| priorityDate |
2018-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |